3696: InSilico Medicine Cayman TopCo - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

InSilico Medicine Cayman TopCo

HKG:3696

SummaryFactSheetFinancial
Price
HK$48.76
Loss Chance
50.9%
3.13JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Life Sciences Tools and Services
7 / 15
Health Care
106 / 245
Hong Kong
?
951 / 2,579
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
Frontage Holdings Corporation
HKG:1521
5.02
HK$1.30
181.69%
Viva Biotech Holdings
HKG:1873
4.12
HK$1.34
43.83%
WuXi XDC Cayman
HKG:2268
6.18
HK$72.80
87.15%
WuXi XDC Cayman
HKG:2268
6.18
HK$72.80
87.15%
WuXi Biologics (Cayman)
HKG:2269
6.60
HK$49.18
76.32%
Jitta Factors
Growth Opportunity (41)
Recent Business Performance (58)
Financial Strength (37)
Return to Shareholders (0)
Competitive Advantage (41)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Operating MarginDeclined
Recent Business PerformanceEarning decline 1801.70% in the last year
Key Stats
Jitta Score
Jitta Line
3.13
100.00%
4.58
362.90%
3.81
220.74%
Life Sciences Tools and Services
5.02
181.69%
4.12
43.83%
6.18
87.15%
COMPANY DESCRIPTION
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. InSilico Medicine Cayman TopCo has a strategic collaboration agreement with Takeda to use its proprietary Pharma.AI, to advance drug candidates. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.
insilico.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.